UK markets closed

AIM ImmunoTech Inc. (0A4Y.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
0.3987-0.0214 (-5.09%)
At close: 04:20PM BST
Full screen
Loading interactive chart…
  • GlobeNewswire

    AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update

    Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications Company to host conference call and webcast today, May 16, at 8:30 AM ET OCALA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the first quarter 2024. As previously announced, the Company will host a conference call and webcast today, Thursday, May 16, 2024, at 8:3

  • GlobeNewswire

    AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

    OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company’s Q1 2024 operational and financial results on Thursday, May 16, 2024, at 8:30 AM ET. The call will be hosted by members of AIM’s leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the c

  • GlobeNewswire

    AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

    OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. AIM Chief Executive Officer Thomas K. Equels commented, “We remain focused on operational execution and the successful continued production